Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Lonza Group Ltd.. (11/12/19). "Press Release: Board Announcement". Basel.

Organisation Organisation Lonza Group AG (SWX: LONN)
  Today Lonza Group (Group)
  Group Lonza Group (Group)
Products Product contract manufacturing (biologicals)
  Product 2 contract manufacturing (drugs)
Person Person Funk, Marc (Lonza 201903–202001 CEO before COO of Pharma+Biotech division joined Lonza 1/09 LEFT 1/20)
     


Lonza announced today that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found. Marc will stay until January 2020 to ensure a smooth hand-over.

In addition, for reasons of good governance, board member Christoph Maeder has been appointed Lead Independent Director by the Board.

Christoph Maeder, Lead Independent Director said: “Albert has agreed to lead the Company on a temporary basis until a successor is in place, for which a search has commenced. The Board respects Marc’s decision and would like to thank him for his service to Lonza and wish him well for his future endeavors.”

Albert Baehny, Chairman said: “I am committed to Lonza, its employees and all its stakeholders and I will ensure that I work in their best interests in the months ahead. The Company has an exciting future in dynamic markets and I am keen to ensure that we maintain our momentum and capture all the opportunities available to us. I look forward to working with colleagues, customers, partners and other stakeholders in the coming months and also to working with the Board in the search for a new Chief Executive Officer to lead the Company in the years ahead.”


About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.


Lonza Contact Details

Dirk Oehlers
Investor Relations Officer
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dr. Kristin Koehler
Investor Relations Director
Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com

David Carter
Head of Communication
Lonza Group Ltd
Tel +41 79 510 1575
david.carter@lonza.com

Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel +41 79 539 0615
sanna.fowler@lonza.com


Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.


Lonza Group Ltd¦ Muenchensteinerstrasse 38 ¦CH-4002 Basel ¦Switzerland +41 61 316 81 11 ¦ www.lonza.com ¦ media@lonza.com

   
Record changed: 2019-11-14

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Lonza Group (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top